Results 251 to 260 of about 790,096 (261)

Pharmacokinetics and Pharmacodynamics of Biosimilar Insulins: Is Clamp Technology Fit for Purpose?

Diabetes Care, 2015
Philip D Home
exaly  

PHARMACEUTICALS Merck deal with South Korea’s Hanwha bolsters move into biosimilars

Chemical & Engineering News Archive, 2011
openaire   +1 more source

The Future of Biosimilar Insulins

Diabetes Spectrum, 2016
exaly  

A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma

Blood, 2016
Wojciech Jurczak, Pratyush Giri
exaly  

Top bar navigation

Frontiers in Public Health
Maria Morais, Pedro L. Ferreira
exaly  

Unchanged Infliximab Serum Concentrations After Switching from the Originator Infliximab to the Biosimilar CT-P13 in Patients with Quiescent Crohn's Disease: A Prospective Study

, 2017
A. Strik, W. van de Vrie, Y. V. van Megen, J. Minekus, T. Rispens, G. D'Haens   +5 more
semanticscholar   +1 more source

EE339 The Biosimilars’ Economic Evaluation in Contrast With Judicializations’ Economic Impacts of the Pharmaceutical Assistance in Brazil

Value in Health
E Tanaka, GK Tanaka, L. Assunção-Costa, E Blay   +3 more
openaire   +1 more source

The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products,

Reactions Weekly, 2012
openaire   +2 more sources

4CPS-259 Impact of switching to biosimilar etanercept in rheumatoid arthritis patients followed in pharmaceutical consultations at a tertiary hospital

Section 4: Clinical pharmacy services
MJ Carvalho, AR Lopes Calvo, J Oliveira, MR Vaz, MR Ferreira, P Soares   +5 more
openaire   +1 more source

Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD.

American health & drug benefits
openaire   +1 more source